CTLA-4/CD152 hFc Chimera, Human
| ¥1200 | |
| Z05200-100 | |
| 
                                             | 
            |
| 
                        
                             | 
                |
| 
                         | 
                |
| ¥1200 | |
| Z05200-100 | |
| 
                                             | 
            |
| 
                        
                             | 
                |
| 
                         | 
                |
| Species | Human | ||||
| Protein Construction | 
                                                                                                                                                                                
  | 
                                                ||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 40.1 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-55 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. | 
                                                    Immobilized Human B7-1, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for CTLA-4/CD152 hFc Chimera, Human, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA. »
                                                    Immobilized Human B7-2, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for CTLA-4/CD152 hFc Chimera, Human, hFc Tag with the EC50 of 8.7ng/ml determined by ELISA. »
                                                    The purity of CTLA-4/CD152 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
                                                    CTLA-4/CD152 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
                                                    Human B7-1, His Tag captured on CM5 Chip via Anti-His Antibody can bind CTLA-4/CD152 hFc Chimera, Human, hFc Tag with an affinity constant of 1.1nM as determined in SPR assay (Biacore T200). »
| Target Background | CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152, is a protein receptor that, functioning as an immune checkpoint, downregulates immune responses.CTLA4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an 'off' switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. | 
| Synonyms | CTLA4; CD152; ICOS; CELIAC3; GRD4; GSE; ALPS5; IDDM12 | 
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.